Functional genomics and the development of pathogenesis-targeted therapies for Kaposi's sarcoma.

@article{McAllister2005FunctionalGA,
  title={Functional genomics and the development of pathogenesis-targeted therapies for Kaposi's sarcoma.},
  author={Shane C. McAllister and Klaus Fr{\"u}h and Ashlee V Moses},
  journal={Pharmacogenomics},
  year={2005},
  volume={6 3},
  pages={235-44}
}
Kaposi's sarcoma (KS) is a multifocal angioproliferative disorder affecting the skin, mucosa and viscera of individuals infected with human herpesvirus-8 (HHV-8; also Kaposi's sarcoma-associated herpesvirus [KSHV]). KS is the most common neoplasm in AIDS patients; the clinical outcome of AIDS-KS is significantly improved by highly active antiretroviral therapy (HAART). However, in Africa, where the severest manifestations of KS occur, there is limited access to these and other effective but… CONTINUE READING